Summary

Market Overview
The Global Antipsychotic Drugs Market was valued at USD 15.29 billion in 2024 and is projected to reach USD 25.48 billion by 2030, expanding at a CAGR of 8.88% during the forecast period. This market serves as a vital component of the pharmaceutical sector, addressing serious mental health disorders such as schizophrenia, bipolar disorder, and treatment-resistant depression. Antipsychotic medications, also known as neuroleptics, are designed to manage and reduce symptoms like hallucinations, delusions, and mood instability by targeting neurotransmitter imbalances, primarily dopamine, in the brain. With mental health conditions on the rise globally, fueled by societal stressors and lifestyle changes, demand for these drugs is escalating. According to the World Health Organization, nearly one in eight people worldwide were living with a mental disorder in 2019. The COVID-19 pandemic further intensified this trend, with significant increases in cases of anxiety and depression. As awareness grows and stigmas diminish, more individuals are seeking treatment, contributing to market expansion. Antipsychotics continue to evolve, offering improved efficacy and tolerability, and playing a key role in long-term psychiatric care and quality-of-life improvement for affected patients.
Key Market Drivers
Rising Prevalence of Mental Health Disorders
The increasing global incidence of psychiatric conditions such as schizophrenia, bipolar disorder, and major depressive disorder is a primary growth driver for the antipsychotic drugs market. This rise is attributed to various factors including changing lifestyles, heightened stress levels, and improved diagnostic capabilities. Greater public awareness and reduced stigma around mental health are prompting more individuals to seek professional care. Consequently, this has led to higher diagnosis rates and an expanding patient population requiring pharmaceutical intervention. Antipsychotic drugs are essential in managing severe mental health symptoms, stabilizing patients, and preventing relapses. Their role in enhancing daily functioning and overall well-being has become increasingly prominent, aligning with the growing focus on holistic mental healthcare.
Key Market Challenges
Adverse Side Effects
A major challenge for the antipsychotic drugs market is the prevalence of adverse effects associated with these medications. Despite the advancements seen with second-generation (atypical) antipsychotics, many patients still experience side effects including significant weight gain, metabolic syndrome, sedation, and sexual dysfunction. These complications can hinder treatment adherence and diminish quality of life. Managing such side effects often requires additional medical oversight and therapeutic adjustments, which can increase healthcare costs and complicate patient care. This challenge underscores the importance of developing newer antipsychotic formulations with improved safety profiles to enhance patient compliance and long-term treatment outcomes.
Key Market Trends
Personalized Medicine Approach
The shift towards personalized medicine is a notable trend shaping the future of the antipsychotic drugs market. Leveraging pharmacogenomics, clinicians are now tailoring treatments to individual genetic profiles, enabling the selection of the most appropriate drug and dosage for each patient. This customized approach minimizes the risk of adverse effects and improves therapeutic efficacy. The integration of genetic testing and data-driven decision-making is helping to move beyond the traditional trial-and-error model, enhancing both clinical outcomes and patient satisfaction. As healthcare systems globally prioritize individualized care, personalized antipsychotic treatment strategies are expected to become a cornerstone in psychiatric therapy.
Key Market Players
• Eli Lily and Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Johnson & Johnson
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• AbbVie Inc.
• Dr. Reddy’s Laboratories Limited
• Otsuka Holdings Co., Ltd.
• Teva Pharmaceutical Industries Ltd
Report Scope:
In this report, the Global Antipsychotic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Antipsychotic Drugs Market, By Application:
o Schizophrenia
o Bipolar Disorder
o Unipolar Disorder
o Dementia
o Others
• Antipsychotic Drugs Market, By Drug Classification:
o First Generation (Typical)
o Second Generation (Atypical)
• Antipsychotic Drugs Market, By Region:
o North America
§ United States
§ Mexico
§ Canada
o Europe
§ France
§ Germany
§ United Kingdom
§ Italy
§ Spain
o Asia-Pacific
§ China
§ India
§ South Korea
§ Japan
§ Australia
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East and Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Antipsychotic Drugs Market.
Available Customizations:
Global Antipsychotic Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Antipsychotic Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Application (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, Others)
5.2.2. By Drug Classification (First Generation (Typical), Second Generation (Atypical))
5.2.3. By Company (2024)
5.2.4. By Region
5.3. Market Map
6. North America Antipsychotic Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Application
6.2.2. By Drug Classification
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Antipsychotic Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Application
6.3.1.2.2. By Drug Classification
6.3.2. Mexico Antipsychotic Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Application
6.3.2.2.2. By Drug Classification
6.3.3. Canada Antipsychotic Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Application
6.3.3.2.2. By Drug Classification
7. Europe Antipsychotic Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Application
7.2.2. By Drug Classification
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Antipsychotic Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Application
7.3.1.2.2. By Drug Classification
7.3.2. Germany Antipsychotic Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Application
7.3.2.2.2. By Drug Classification
7.3.3. United Kingdom Antipsychotic Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Application
7.3.3.2.2. By Drug Classification
7.3.4. Italy Antipsychotic Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Application
7.3.4.2.2. By Drug Classification
7.3.5. Spain Antipsychotic Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Application
7.3.5.2.2. By Drug Classification
8. Asia-Pacific Antipsychotic Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Application
8.2.2. By Drug Classification
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Antipsychotic Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Application
8.3.1.2.2. By Drug Classification
8.3.2. India Antipsychotic Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Application
8.3.2.2.2. By Drug Classification
8.3.3. South Korea Antipsychotic Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Application
8.3.3.2.2. By Drug Classification
8.3.4. Japan Antipsychotic Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Application
8.3.4.2.2. By Drug Classification
8.3.5. Australia Antipsychotic Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Application
8.3.5.2.2. By Drug Classification
9. South America Antipsychotic Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Application
9.2.2. By Drug Classification
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Antipsychotic Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Application
9.3.1.2.2. By Drug Classification
9.3.2. Argentina Antipsychotic Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Application
9.3.2.2.2. By Drug Classification
9.3.3. Colombia Antipsychotic Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Application
9.3.3.2.2. By Drug Classification
10. Middle East and Africa Antipsychotic Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Application
10.2.2. By Drug Classification
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Antipsychotic Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Application
10.3.1.2.2. By Drug Classification
10.3.2. Saudi Arabia Antipsychotic Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Application
10.3.2.2.2. By Drug Classification
10.3.3. UAE Antipsychotic Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Application
10.3.3.2.2. By Drug Classification
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. PESTLE Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. Competitive Landscape
15.1. Eli Lily and Company
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. AstraZeneca plc
15.3. GlaxoSmithKline plc
15.4. Johnson & Johnson
15.5. Otsuka Pharmaceutical Co, Ltd.
15.6. Pfizer Inc.
15.7. AbbVie Inc.
15.8. Dr. Reddy’s Laboratories Limited
15.9. Otsuka Holdings Co., Ltd.
15.10. Teva Pharmaceutical Industries Ltd.
16. Strategic Recommendation
17. About Us & Disclaimer